 |
Final Scientific Program |
|
Wednesday, September 16, 2009
|
| 12:00–18:30 |
Registration |
| 18:30–19:30 |
Opening Ceremony-Welcome address |
| 19:30–20:30 |
Welcome Reception |
|
Thursday, September 17, 2009
|
| |
| 08:40–11:00 |
Session I: Biology of metastasis and tumor dormancy
CHAIR: Klaus Pantel, Danny R. Welch
08:40-08:50
Introduction into the Biology and clinical relevance of micrometastasis
Klaus Pantel, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
08:50-09:15
Qualifying of Circulating Tumor cells as biomarkers in castration resistant prostate cancer: The “Liquid Biopsy”
Howard I. Scher, Memorial Sloan - Kettering Cancer Center, New York, USA
09:15-09:40
Metastasis suppressor leading to metastatic cell dormancy
Danny R. Welch, University of Alabama, Birmingham, AL, President, Metastasis Research Society, USA
09:40-10:05
EDG2 (LPA1) controls the outgrowth of micrometastatic breast cancer cells: Basic and translational approaches
Patricia S. Steeg, National Cancer Institute. NCI, Bethesda, USA
10:05-10:30
Epithelial-mesenchymal transition and its significance for bone marrow micrometastasis formation
Jean Paul Thiery, Institute of Molecular and Cell Biology, Biopolis, Singapore
10:30-10:55
Differential microRNA regulation by the three Akt isoforms in IGF-treated and hypoxia exposed cells: Effects on EMT, stem cell renewal and cell survival and proliferation
Philip N. Tsichlis, Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
|
|
11:00–11:15
|
Coffee Break
Poster Session Viewing
Exhibition visit
|
|
11:15–13:00
|
Session II: Biology of metastasis and tumor dormancy
CHAIR: Georgia Sotiropoulou, Jean Paul Thiery
11:15-11:40
Expanding and quantifying molecular signatures of CTCs
Jonathan Uhr, University of Texas Southwestern Medical School, Dallas, Texas, USA
11:40-12:05
Stress signaling and the microenvironment as regulators of tumor cell dormancy
Julio Aguirre-Ghiso, Mount Sinai School of Medicine, New York, NY, USA
12:05-12:30
Imaging experimental models of metastasis and dormancy
Ann F. Chambers, University of Western Ontario, London, Canada
12:30-13:00
Protumor immunity and breast cancer development
Lisa M. Coussens, University of California, San Franscisco, USA
|
|
13:00–14:30
|
Lunch Break
Poster Session
Exhibition visit
|
|
14:30–16:20
|
Selected Oral Presentations Session I: Biology of metastasis and circulating tumor cells
CHAIR: Ann Chambers, Lisa M. Coussens
O1
Epithelial-mesenchymal transition (EMT) has immunomodulatory function in breast cancer
J.M. Reuben, B.N. Lee, M. Mego, H. Gao, E.N. Cohen, C. Li, E. Andreopoulou, M. Cristofanilli, S.A. Mani
O2
Stem cell and epithelial-mesenchymal transition markers are frequently over-expressed in circulating tumor cells of metastatic breast cancer patients
B. Aktas, M. Tewes, T. Fehm, S. Hauch, R. Kimmig, S. Kasimir-Bauer
O3
EMT induction by A Gene in CD133 expressing cells Induced Tumorogenesis and Poorer Prognosis in CRC cases
K. Mimori, T. Yokobori, H. Ishii, M. Iwatsuki, K. Pantel, M. Mori
O4
Acquisition of HER2/NEU over-expression on circulating tumor cells (CTCS) in patients (PTS) with advanced breast cancer (ABC) during chemotherapy
F. Nole, E. Munzone, L. Zorzino, C. Cassatella, M.C. Casadio, E.Verri, M. Cossu-Rocca, G. Aurilio, A. Sciandivasci, A. Esposito, D. Cullura, L. Adamoli, A. Goldhirsch, M. Sandri
O5
Bone marrow detection of a multimarker mRNA panel including TWIST1 is an independent prognostic factor in patients with operable breast cancer
K. Tjensvoll, S. Oltedal, B. Gilje, R.Heikkila, F.V. Shammas, J.T. Kvaloy, R. Smaaland, O. Nordgard
O6
Colon cancer and epithelial-mesenchymal transition: Signatures, novel markers and trail therapeutics
A. Voulgari, T. Joyce, E. Oikonomou, M. Kalogeropoulou, E. Medico, L. Andera, A. Pintzas
O7
Comparison of Circulating Tumor Cells (CTCs) in Peripheral Blood and Disseminated Tumor Cells in the Bone Marrow (DTC-BM) of Breast Cancer patients
C. Schindlbeck, B. Rack, J. Juckstock, C. Jenderek, U. Andergassen, M. Guenthner-Biller, H. Sommer, W. Janni, K. Friese
O8
A tumor protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition
G. Pampalakis, E. Prosnikli, T. Agalioti, A. Vlahou, V. Zoumpourlis, G. Sotiropoulou
O9
Characterization of circulating tumor cells by fluorescence in situ hybridization
J.F. Swennenhuis, A.G.J. Tibbe, R. Levink, R.C.J. Sipkema, L.W.M.M. Terstappen
O10
Re-programming breast cancer stem cells
F.M. Robertson, W.A. Woodward, M. Cristofanilli
|
|
16:20–16:45
|
Coffee Break
Poster Session Viewing
Exhibition visit
|
|
16:45–18:30
|
Session III: Novel Technologies for the isolation, detection and characterization of CTCs and DTCs
CHAIR: Tanja Fehm, Peter Kuhn
16:45-17:10
Enumeration of circulating tumor cells
Leon W.M.M. Terstappen, University of Twente, Enschede, The Netherlands
17:10-17:35
Development of a Membrane Microfilter Device for capture and characterization of Circulating Tumor Cells (CTC) in blood
Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL, USA
17:35-18:00
EPISPOT assay: Detection of viable disseminating tumor cells in solid tumor patients
Catherine Alix-Panabières, University Medical Center – Lapeyronie Hospital, Montpellier, France
18:00-18:25
Multiplexed molecular methods for the detection and characterization of CTCs
Evi Lianidou, Dept. of Chemistry, University of Athens, Greece
|
|
18:30–19:30
|
PLENARY LECTURE I
Chair: Evi Lianidou
The impact of real-time PCR on cancer diagnostics
Carl T. Wittwer, University of Utah, School of Medicine, Salt Lake, USA
|
|
Friday, September 18, 2009
|
| |
|
08:50–11:00
|
Session IV: CTCs and DTCs as tumor biomarkers
CHAIR: Massimo Cristofanilli, Dave S.B. Hoon
08:50-09:15
The systemic progression of prostate cancer
Bernhard Polzer, Division of Oncogenomics, University of Regensburg, Regensburg, Germany
09:15-09:40
Prognostic significance of CTCs in early breast cancer
Dimitris Mavroudis, Medical Oncology, University of Crete, Greece
09:40-10:05
Determination of HER2 status in circulating and disseminated tumor cells (CTC/DTC)
Tanja Fehm, University of Tübingen, Tübingen, Germany
10:05-10:30
Disseminated Tumor Cells in Breast Cancer Patients
Bjorn Naume, The Norwegian Radium Hospital, Oslo, Norway
10:30-10:55
Disseminated Tumor Cells vs Circulating Tumor Cells
Jean-Yves Pierga, Institute Curie, Paris, France
|
|
11:00–11:15
|
Coffee Break
Poster Session Viewing
Exhibition visit
|
|
11:15–12:00
|
PLENARY LECTURE II
CHAIR: Dimitris Mavroudis
Detection and characterization of disseminating tumor cells: Challenges and Perspectives
Klaus Pantel, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
|
|
12:00–13:00
|
PLENARY LECTURE III
CHAIR: Evi Lianidou
The role of microRNAs in metastasis
George A. Calin, M. D. Anderson Cancer Center, Houston, Texas, USA
|
|
13:00–14:30
|
Lunch Break
Poster Session
Exhibition visit
|
|
14:30–16:20
|
Selected Oral Presentations Session II: Novel Methodologies for CTCs isolation, detection and characterization
CHAIR: Bjorn Naume, Richard J. Cote
O11
A novel method to capture and characterize bone marrow micrometastases in patients with breast cancer
M. Balic, H. Lin, J.B. Geigl, S. Zheng, S. Langner, M.R. Speicher, Y.C. Tai, R.J. Cote
O12
Detection of tumor stem cells among circulating epithelial tumor cells
K. Hekimian, E.-L.Stein, U. Pachmann, K. Pachmann
O13
External quality assurance of circulating tumor cell enumeration by automated immunomagnetic enrichment and image cytometry: A pilot study
J. Kraan, M. Strijbos, S. Sleijfer, J.A. Foekens , J.W. Gratama
O14
Improved detection of circulating tumor cells (CTCS) in breast cancer through enrichment with ANTI-CD146
B. Mostert, J. Kraan, P. van der Spoel, J. Bolt-de Vries, A.M. Sieuwerts, M. Schutte, J.W.M. Martens, J. W. Gratama, J.A. Foekens, S. Sleijfer
O15
Microfluidic technology meets cancer care: Are we there yet? ; Milestones and challenges
S. Nagrath, S. Maheswaran, L. Sequist, L. Ulkus, B. Brannigan, C.V. Collura, D. Irimia, A.J. Iafrate, S. Digumarthy, A. Muzikansky, J. Settleman, T.J. Lynch, D.A. Haber, M. Toner
O16
High throughput/high content capture and typing of rare cells for cancer diagnosis and prognosis
L. Saias, A.E. Saliba, J.Y. Pierga, P. Vielh, F. Farace, L. Malaquin, J.L. Viovy
O17
Quantitative real-time PCR and fine-tiling array-CGH for single tumor cell based analysis on the example of the EGFR gene
J. Hannemann, S. Meyer-Staeckling, S.A. Joosse, I. Alpers, S. Riethdorf, D. Kemming, K. Pantel, B. Brandt
O18
Development and validation of a real-time multiplex PCR assay for the simultaneous quantification of CK-19, MAGE-A3, HER-2 and PBGD in circulating tumor cells of breast cancer patients
A. Strati, A. Markou, N. Malamos, V. Georgoulias, E.S Lianidou
O19
Development and validation of a multiplexed PCR-coupled liquid bead array for gene expression in circulating tumor cells
A. Markou, A. Strati, N. Malamos, V. Georgoulias, E.S Lianidou
|
|
16:20–16:45
|
Coffee Break
Poster Session Viewing
Exhibition visit
|
|
16:45–18:50
|
Session V: CTCs: Clinical trials and cancer therapeutics
CHAIR: Vasilis Georgoulias, Jean-Yves Pierga
16:45-17:10
Monitoring CTCs in adjuvant therapy in breast cancer (The SUCCESS trial)
J. Wolfgang Janni, Klinikum der Heinrich-Heine-Universitat Düsseldorf, Germany
17:10-17:35
CTCs in breast cancer: Advanced tools for tailored therapy?
Massimo Cristofanilli, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
17:35-18:00
Challenges in Clinical trials on CTCs
Michail Ignatiadis, Jules Bordet Institute, Brussels, Belgium
18:00-18:25
Circulating Tumor Cells prognostic utility Validated in a prospective international randomized clinical trial
Dave S.B. Hoon, John Wayne Cancer Institute, Santa Monica, CA, USA
18:25-18:50
Lessons learnt from circulating tumor cell (CTC) studies in castration-resistant prostate cancer (CRPC) patients treated with abiraterone acetate
Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom
|
|
20:30
|
Gala Dinner
|
Saturday, September 19, 2009
|
| |
|
08:50-11:00
|
Session VI: Gene signatures, CTCs and cancer stem cells
CHAIR: Klaus Pantel, Michael Clarke
08:50-09:15
Taking gene expression profiling to the clinic: When will molecular signatures become relevant to patient care?
Christos Sotiriou, Jules Bordet Institute, Brussels, Belgium
09:15-09:40
Breast Bioclassifier: A clinical diagnostic test for subtyping and predicting risk of relapse in breast cancer
Philip Bernard, University of Utah, School of Medicine, USA
09:40-10:05
Breast cancer stem cells-implications for therapeutic targeting
Hasan Korkaya, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
10:05-10:30
Dormancy in normal and malignant Stem Cells
Andreas Trumpp, German Cancer Research Center (DKFZ), Heidelberg, Germany
10:30-10:55
Credentialing of Circulating Tumor Cells - Making the connection between the primary and metastatic tumor
Peter Kuhn, The Scripps Research Institute, La Jolla, California, USA
|
|
11:00–11:15
|
Coffee Break
Exhibition visit
|
|
11:15–12:15
|
PLENARY LECTURE IV
CHAIR: Dimitris Mavroudis
Molecular analysis of normal and malignant epithelial stem cells
Michael F. Clarke, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Palo Alto, California, USA
|
|
12:15–13:00
|
Lunch Break
Exhibition visit
|
|
13:00–14:50
|
Selected Oral Presentations Session III: Clinical Significance of CTCs detection
CHAIRS: Sophia Agelaki, Michail Ignatiadis
O20
Transcriptomic profiles and CTC detection in primary breast cancer
F.C. Bidard, F. Reyal, F. Valet, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, R. Salmon, A. Vincent-Salomon, L. Mignot, M. Marty, J.Y. Pierga
O21
Classification of EpCAM+ CD45- cytokeratin+ objects versus survival in castration resistant prostate cancer
F. Coumans, C.J.M. Doggen, G. Attard, J.S. de Bono, L.W.M.M. Terstappen
O22
CEC and CTC in stage IV breast cancers treated with bevacizumab (Bv) and chemotherapy (CT)
F.C. Bidard, C. Mathiot, A. Degeorges, P. Formento, M. Francoual, R. Delva, X. Pivot, P. de Cremoux, H. Cure, B. Audhuy, L. Bobadilla, G. Milano, J.Y. Pierga
O23
Patterns of relapse not influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus
B. Rack, C. Schindlbeck, J. Jueckstock, U. Andergassen, C. Jenderek, M. Günthner-Biller, P. Hepp, H. Sommer, K. Friese, W. Janni
O24
Circulating tumor cells in north central cancer treatment group breast clinical trials (N0234/336/338/436/437)
M.M. Reinholz, K.A. Kitzmann, K.S. Tenner, D.W. Hillman, T.J. Hobday, V. Roy, A. Moreno-Aspitia, D. Northfelt, J. Allred, B. LaPlant, A.C. Dueck, E.A. Perez, W.L. Lingle
O25
Circulating tumor cell (CTC) as a diagnostic marker in primary lung cancer
F. Tanaka, K. Yoneda, M.N. Kondo, Hashimoto, T. Takuwa, S. Matsumoto, Y. Okumura, T. Tsujimura, K. Fukuoka, T. Nakano, S. Hasegawa
O26
Disseminated tumour cells in the bone marrow represent the strongest prognosticator of disease-free and overall survival in esophageal cancer: Evaluation of 304 cases
Y.K. Vashist, K.E. Effenberger, K. Pantel, J.R. Izbicki, E.F. Yekebas
O27
Real-time quantitative (RQ)-PCR by the europe against cancer (EAC) protocol in acute promyelocytic leukemia (APL)
M. Garofalaki, M. Pagoni, I. Tziotziou, E. Nikolou, A. Balta, M. Vagia, I. Tzannou, I. Baltadakis, E. Nikiforakis
O28
Effect of chemotherapy on the CK-19 mRNA-positive circulating tumor cells (CTCs) and correlations with the clinical outcome in patients with early breast cancer
N. Xenidis, S. Apostolaki, M. Perraki, S. Agelaki, K. Kalbakis, N. Androulakis, L. Vamvakas, S. Kakolyris, Α. Xirafas, D. Mavroudis, V. Georgoulias
O29
Genomic profiles of disseminated tumor cells in metastatic breast cancer patients
R.R. Mathiesen, R. Fjelldal, L.O. Baumbusch, J.B. Geigl, S. Riethdorf, O. Mauermann, I.J. Schneider, E.U. Due, A-L. Børresen-Dale, K. Pantel, M.R. Speicher, B. Naume
|
|
15:00–15:15
|
Presentation of best poster presentation award - Closing Remarks
Evi Lianidou, Dept. of Chemistry, University of Athens, Greece
|
|
16:00
|
Visit to the Acropolis and New Acropolis Museum
|
|
|
Platinum Sponsor
|
|
|
| |
|
Gold Sponsors
|
|
|
|
|
|
|
| |
|
Silver Sponsors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| |
|
BronzeSponsors
|
|
|
|
|
|
|
| |
|
Sponsors
|
|
|
|
KIRIAKIDIS I.M. S.A.
|
|
|
|
|
|
Print